0.02
-0.0027(-15.17%)
Currency In USD
| Previous Close | 0.02 |
| Open | 0.02 |
| Day High | 0.02 |
| Day Low | 0.02 |
| 52-Week High | 0.58 |
| 52-Week Low | 0.01 |
| Volume | 359,591 |
| Average Volume | 121,875 |
| Market Cap | 600,137 |
| PE | -0.01 |
| EPS | -1.1 |
| Moving Average 50 Days | 0.02 |
| Moving Average 200 Days | 0.11 |
| Change | -0 |
If you invested $1000 in Viracta Therapeutics, Inc. (VIRX) 10 years ago, it would be worth $0.08 as of July 01, 2025 at a share price of $0.015. Whereas If you bought $1000 worth of Viracta Therapeutics, Inc. (VIRX) shares 5 years ago, it would be worth $1.34 as of July 01, 2025 at a share price of $0.015.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Viracta Therapeutics Announces Wind Down of Operations
GlobeNewswire Inc.
Feb 05, 2025 10:00 PM GMT
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced today
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives
GlobeNewswire Inc.
Dec 26, 2024 9:30 PM GMT
SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma
GlobeNewswire Inc.
Nov 06, 2024 9:30 PM GMT
Company implementing 42% reduction in force and resizing its Board of Directors to six seats from tenSAN DIEGO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the